Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 1

Interventions

Specimen Handling 108Magnetic Resonance Spectroscopy 77Biopsy 76pembrolizumab 59Cyclophosphamide 49fludarabine 40Carboplatin 25Nivolumab 24Cetuximab 23venetoclax 21Radiotherapy 21Cisplatin 21Bevacizumab 20atezolizumab 18X-Rays 18Radiation 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Gemcitabine 15Temozolomide 14Paclitaxel 14Leucovorin 14Irinotecan 14Cytarabine 14durvalumab 13Pemetrexed 13Azacitidine 13Oxaliplatin 12CTLA-4 Antigen 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Antineoplastic Agents × 30 days × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡